European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

The European medical isotope programme: Production of high purity isotopes by mass separation

Descrizione del progetto

Infrastruttura europea per la produzione di radionuclidi

La medicina nucleare utilizza molecole radioattive (i cosiddetti radiofarmaci) e le loro radiazioni per fornire informazioni diagnostiche e curare varie condizioni cliniche, come il cancro. Gli elementi radioattivi, noti come radionuclidi, possiedono energia in eccesso che viene rilasciata da diversi tipi di decadimento radioattivo. L’obiettivo chiave del progetto PRISMAP, finanziato dall’UE, è quello di istituire un’infrastruttura europea e un punto di accesso comune per i ricercatori e i medici del settore. Il consorzio creerà una fonte sostenibile di radionuclidi non convenzionali altamente puri per gli sviluppi in medicina, nonché protocolli e servizi per l’industria farmaceutica e il settore sanitario, in un programma europeo sostenibile di radionuclidi medici.

Obiettivo

PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP will create a single-entry point for a fragmented user community distributed amongst universities, research centres, industry and hospitals, in a similar way as the National Isotope Development Center NIDC supported by the Department of Energy (DOE) has provided radionuclide sources for users in the USA. PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It further receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA). Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures. The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe - theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens’ life.

Invito a presentare proposte

H2020-INFRAIA-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-INFRAIA-2020-1

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE
Contribution nette de l'UE
€ 1 032 220,00
Indirizzo
ESPLANADE DES PARTICULES 1 PARCELLE 11482 DE MEYRIN BATIMENT CADASTRAL 1046
1211 GENEVE 23
Svizzera

Mostra sulla mappa

Regione
Schweiz/Suisse/Svizzera Région lémanique Genève
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 032 220,00

Partecipanti (22)